Recorded concentrations of the tumour-associated glycoprotein 72 (TAG-72) in ovarian cancer patients after repeated infusion of the antibody B72.3 were found to be falsely elevated when measured with an homologous immunometric assay involving the anti-TAG-72 antibody B72.3 (Test 1), or with an heterologous assay involving CC49 capture and B72.3 detector antibodies (Test 2). Test l yielded falsely elevated values up to l O 4 kU/1. Test 2 gave slightly false positive elevations up to 10 2 kU/l for only some of the samples with very high false-positive values in Test l. The interfering serum components bound to Protein G-Sepharose and could be precipitated with perchloric acid or by heating serum samples to 100 °C. Addition of non-specific murine immunoglobulins only partly suppressed false-positive values in both tests. Our results suggest that this interference is caused by human anti-B72.3 IgG indüced by B72.3 application, which to some extent specifically binds to determinants of the B72.3 antibody. Heat extraction of serum samples effectively eliminated interferences probably caused by anti-idiotypic antibodies, but did not affect real TAG-72.
Introduction
The monoclonal antibody B72.3 recognises a carbohydrate antigen on the tumour-associated glycoprotein 72 (TAG-72) which is expressed in the majority of human epithelial cancers, including adenocarcinomas of the stomach and ovary (1) (2) . Because the antigen is released into the circulation by tumpurs, monitoring of senim TAG-72 is used for assessnaent of the course of disease of patients with gastric cancer (3) . Furthermore it has been proposed äs an additional marker in ovarian cancer patients (4) . The serum concentration of TAG-72 can be measured by mearts of the immunometric "twosite sandwich" technique using the antibody B723 äs both the capture and the detector antibody (5) , or in an heterologous assay design with the monoclonal antibody CC49 (directed against a separate epitope on the TAG-72 molecule) äs capture antibody, and labelled B72.3 antibody for detection (6) .
There have been a number of reports recently suggesting clinical use of immunoscintigraphy with the monoclonal antibody B72.3 for the management of patients with ovarian cancer (7) (8) . It is well known that a percentage of patients after exposure to murine immunoglobulins develop human anti-murine antibodies which can interfere with diagnostic tests using murine antibodies. Aniong antibodies directed against determinants comrnon to all murine antibodies (anti-iso/allotypic), antiidiotypic antibodies directed against idiotopes within the hypervariable region of the applied antibodies can also be formed (9) (10) . Anti-iso/allotypic human anti-murine antibodies interfere with all diagnostic tests involving murine antibodies (11 -14) . In contrast, anti-idiotypic human anti-murine antibodies can interfere only in assays which use the antibody applied in vivo (or one that has an antigen binding site which cross-reacts with the anti-idiotypic human anti-murine antibodies). When this antibody is employed äs both the capture and the detector antibody, anti-idiotypic antibodies can cause a falsely high assay response by cross-linking capture and detector antibodies (15) (16) , While interference by anti-iso/ allotypic human anti-murine antibodies can be eliminated by addition of non-specific murine immunoglobulins (14) , interference by anti-idiotypic human anti-murine antibodies can only be prevented by using capture (or detector) antibodies different from the antibody applied in vivo (17) .
The aim of the present study was to evaluate the effect of repeated administration of the antibody B72.3 on the determination of TAG-72 when a homologous TAG-72 assay involving only B72.3 antibodies, or an heterologous assay involving CC49 capture and B72.3 detector antibodies, is used. We detected falsely high results after B72.3 infiision with both assays, obviously caused by human anti-B72.3 antibodies. We examined the specificity of the interfering antibodies and established a simple procedure to eliminate interference, which is suitable for routine measurement of TAG-72 in patients treated with the antibody B72.3.
Materials and Methods

Patients and serum samples
All serum samples examined were obtained routinely during follow up of ovarian cancer patients (Stage II1/IV FIGO). The samples were aliquoted and stored at -20 °C until analysis.
One hundred and fifty two samples were drawn from 15 patients who had received one or more inftisions of l mg of the anti-TAG-72 antibody B72.3 (Oncoscint; Eurocetus, Frankfurt, Germany). The procedures followed in this study were in accordance with the Standards of the ethical committee of our faculty. Twenty five samples drawn from 6 of these patients before antibody treatinent served äs control. An additional 36 control samples were obtained from 13 other ovarian cancer patients not treated with murine antibodies.
l ml of serum samples diluted 2-fold with phosphate buffer (0.02 mol/1 sodium phosphate, pH 7.0) to the 3 ml column equilibrated with phosphate buffer. After 5-minutes incubation at rooxn temperature, the column was washed with 30 ml phosphate buffer to elute the unadsorbed fraction. The adsorbed IgG fraction was eluted with 15 ml of elution buffer (0.1 mol/1 glycine-HCl, pH 2.7). The eluate was neutralized immediately with 1.5 ml neutralizing buffer (l mol/1 tris/hydroxymethyl)-aminornethane-HCl, pH 9.0). Both the wash fraction äs well äs the eluate were concentrated using Centricon-30 concentrators (Amicon, Witten, Germany) to a final volume of 0.5 ml.
Precipitation of serum IgG
To eliminate interfering human antibodies, serum IgG was precipitated with perchloric acid or by a heat extraction procedure.
Precipitation with perchloric acid was carried out accordtng to Kim et al. (19) with slight modification. Serum (0.4 ml) was diluted with 0.4 ml NaCl (0.15 mol/1), then mixed with 0.8 ml perchloric acid (1.2 mol/1). The fesulting precipitate was centrifuged at 1200 g for 10 min, and l .2 ml of the supernatant was mixed in a separate test tube with 0.21 ml of a mixture of 8.2 ml KOH (5 mol/1) + 5.0 ml K 2 HPO 4 (3 mol/1). The precipitated KC1O 4 was centrifuged at 1200 g for 10 min and the resulting supernatants were stored frozen at -20 °C until assay. Heat extraction was carried out according to Kim et al. (20) with slight modification. In disposable glass tubes, 0.2 ml serum was mixed with 0.4 ml sodium äcetate büffer (0.2 mol/1 sodium äcetate, pH 5.0). The tubes were covered with glass beads and incubated for 10 min in a boiling water bath. At the end of incubation the samples were cooled on ice for 5 min, then centrifuged at 1200 g for 10 min. The supernatants were stored frozen at -20 °C until assay.
Blocking of human anti-murine antibodies activity
To block anti-iso/allotypic antibodies, non-specific murine IgG (Sigma, Deisenhofen, Germany) (OJ01 ml; 16.6 g/l) was added to the native serum samples (0.24 ml).
Determination of TAG-72
TAG-72 was measured with the B72.3-M-K-S (Test 1; Sorin Biomedica, Düsseldorf, Germany) and the ELSA CA 72-4 (Test 2; Isotopen Diagnostik CIS, Dreieich, Germany). Both tests are solidphase immunoradiometric assays for TAG-72. In Test l, the antibody B72.3 is used äs both the immobilized and the labelled antibody. In Test 2, the monoclonal anti-TAG-72 antibody CC49, which recognizes a separate epitope on the TAG-72 antigen (18) , is used äs immobilized antibody; the antibody B72.3 serves only äs detector antibody. In Test l, bindings of both antibodies takes place simultaneously during a single incubation Step. In Test 2, the detector antibody is added after all serum components not bound to the capture antibody have been removed by an additional washing step. Both tests were performed according to the manufacturer's instructions.
Determination of human serum IgG
Human serum IgG was determined by radial immunodifrusion on LC-Partigen IgG plates (Behring, Marburg, Germany).
Removal of interfering IgG from serum samples
Interfering IgG were removed by affmity chromatography on Protein G-Sepharose (Pharmacia, Freiburg, Germany). We applied
Statistics and calculation
Linear regression analysis was performed by means of the Passing & Bablok method (21) . As a measure of scatter of data pqints of the control collective, we calculated the geometric meaa with the 99% tolerance interval for the ratio XI/YI, where Xi and Yj are the TAG-72 concentrations measured with the respective test kits in one sample äs previously described (17) . A data point (X a ; YJ was classified äs deviating from the relationship of control samples when the ratio X a /Y a exceeded the respective tolerance limits of the control collective.
Results
Identification of samples containing interfering antibodies
Serum samples obtained from patients after antibody treatment were screened for the presence of interfering anti-B72. 3 measured. The fact that there was no clinical evidence of disease suggested that the increase of the TAG-72 concentration in both assays was false and that this was due to anti-B72.3 antibodies formed after infusion of the antibody B72.3.
To confirm that the observed interferences were indeed due to human anti-B72.3 antibodies, we attempted to remove possible interfering antibodies by means of affmity chromatography on protein G-Sepharose (tab. 1): using two serum samples from two patients after repeated antibody infusion, it was found that the TAG-72-like material reacting with the homologous Test l was absorbed almost quantitatively by protein G-Sepharose; 77-81% of the applied TAG-72-like material was recovered in the subsequent eluate. Also, the TAG-72-like material reacting with the heterologous Test 2 was absorbed, and 80-98% was recovered in the subsequent eluate. In contrast, when a control sample was used, 70% and 78% of the TAG-72 activity measured with Test l and Test 2, respectively, passed through the column, and no TAG-72 activity was found in the subsequent eluate. For all samples, serum IgG was absorbed quantitatively; 82-89% was recovered in the eluate.
Elimination of interfering human anti-B72.3 antibodies
To establish a simple method for the elimination of interfering anti-B72.3 antibodies, we examined heat extraction äs well äs perchloric acid treatment of serum samples for their effects on interfering antibodies and real TAG-72. Both procedures effectively eliminated false positive TAG-72-like activity measured with Test l äs well äs Test 2 in two samples drawn after treatment with the antibody B72.3; the TAG-72 concentration of a control sample was not altered. Serum IgG was removed completely from all samples (tab. 2).
Because the heat extraction was easier to perform than the precipitation with perchloric acid, we measured the TAG-72 concentration of 10 fiirther control samples before and after heat treatment to validate that this procedure did not affect real TAG-72. The TAG-72 concentrations measured in these samples (Test 1: 18-127 kU/1; Test 2: 11-137 kU/1) were almost completely recovered after heat treatment with both Test l (mean recovery 97%, ränge 78%-110%) äs well äs Test 2 (mean recovery 101%, ränge 81%-126%) indicating that the real TAG-72 concentration was not affected. 
Discussion
This study demonstrates that jn a significant number of serum samples obtained fromK)varian cancer patients af- While anti-iso/allotypic human anti-murine antibodies can be blocked by noh-specific murine IgG, interferences by anti-idiotypic antibodies can only be eliminated by removing the interfering antibodies. Different methods are proposed for removing interfering serum IgG, including affinity chromatography on Protein A, Protein G or anti-human IgG (13, (15) (16) (17) , precipitation with polyethylene glycol (13) or perchloric acid (19) , and heating to 90 °C (13) . It has been reported previously that TAG-72 is heat-stable and soluble in perchloric acid (22) (23) . This is in accordance with our results, which show that the TAG-72 concentrations measured in the control samples were not affected by heating to 100 °C or precipitation with perchloric acid, whereas interfering human anti-B72.3 was effectively removed by both procedures. Our data demonstrate that in samples containing interfering anti-B72.3 antibodies, the TAG-72 concentration can be determined correctly after pretreatment by heat extraction. However, the samples are diluted during heat extraction (3-fold) and precipitation with perchloric acid (4.7-fold), which decreases the analytical sensitivity of the measurement.
When the TAG-72 concentration is monitored in patients treated with the antibody B72.3, one should be aware of the possibility of interference from newly formed anti-B72.3 antibodies. To exclude this interference, samples obtained after infusion of antibodies should be pretreated to remove interfering serum IgG.
